Amyloidosis Foundation Research Grant

Amyloidosis Foundation Research Grant

Funder: The Amyloidosis Foundation (MI, US)
Website: amyloidosis.org
Contact: [email protected] | 248-922-9610 | 7151 N. Main St. Ste. 2, Clarkston, MI 48346

Overview

The Amyloidosis Foundation offers research grants to support investigations into amyloidosis causes, treatments, and management. This is an annual grant program that funds peer-reviewed research projects.

Focus Areas

Grants support research across multiple amyloidosis types and research approaches:
• AL Amyloidosis: Gene expression changes, light chain biology, cell therapy, therapeutic targets
• ATTR Amyloidosis: Both hereditary (hATTR) and wild-type (ATTRwt) forms
- TTR aggregation and fibril formation - Cardiac amyloidosis (transthyretin cardiac amyloidosis) - Polyneuropathy
• ApoA1 Amyloidosis: Precision therapies and genome editing
• Renal Amyloidosis: Organoid models, immune microenvironment, therapeutic development
• Biomarkers: Early detection and disease progression monitoring
• Therapeutic Development: Peptide inhibitors, cell therapy, gene therapy, drug repurposing
• Clinical Research: Quality of care, disparities in diagnosis and treatment

Eligibility

Grants have been awarded to researchers at:
• Academic medical centers and universities
• Hospital-based research programs
• International institutions
• All career levels from PhD students to established MDs

Geographic Scope

Domestic: Boston University, Columbia University, Johns Hopkins, Mayo Clinic, Brigham and Women's Hospital, Tufts Medical Center, Yale University, Memorial Sloan Kettering, City of Hope, Louisiana State University, University of Alabama, University of Pennsylvania, University of Tennessee

International: Institutions in Italy, Portugal, Sweden, Israel

Award History

Recent awardees (2026 awards):
• Shabatun Islam, MD (Boston University Medical Center) - Muscle mass and frailty in TTR cardiac amyloidosis
• Aaron Feinstein, PhD (Tufts Medical Center) - IgG light chain fibrillogeniesis
• Marcel A. Chuecos Rincon, PhD (Baylor College of Medicine) - Precision therapies for ApoA1 amyloidosis

2025 awards:

Michael S. Hughes, MD (Columbia University) - CAR macrophage therapy in AL amyloidosis

Emre Karayol, MD (Brigham and Women's Hospital) - Proteostasis network in AL amyloidosis (follow-up grant)

Taxiarchia Kourelis, MD (Mayo Clinic) - Human organoid model for renal AL amyloidosis

Historical awards dating back to 2014 demonstrate sustained funding commitment.